19 results on '"Winn, Virginia D."'
Search Results
2. Uteroplacental Ischemia Is Associated with Increased PAPP-A2
- Author
-
Lamale-Smith, Leah M, Gumina, Diane L, Kramer, Anita W, Browne, Vaughn A, Toledo-Jaldin, Lilian, Julian, Colleen G, Winn, Virginia D, and Moore, Lorna G
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Contraception/Reproduction ,Pediatric ,Clinical Research ,Cardiovascular ,Perinatal Period - Conditions Originating in Perinatal Period ,Reproductive health and childbirth ,Adult ,Altitude ,Cohort Studies ,Female ,Humans ,Placenta ,Pre-Eclampsia ,Pregnancy ,Pregnancy-Associated Plasma Protein-A ,Ultrasonography ,Doppler ,Uterine Artery ,Uterus ,Vascular Resistance ,Young Adult ,High altitude ,Hypoxia ,PAPP-A2 ,Pappalysin-2 ,Preeclampsia ,Uterine artery pulsatility index and blood flow ,Paediatrics and Reproductive Medicine ,Obstetrics & Reproductive Medicine ,Reproductive medicine ,Midwifery - Abstract
Residence at high altitude (> 2500 m) has been associated with an increased frequency of preeclampsia. Pappalysin-2 (PAPP-A2) is an insulin-like growth factor binding protein-5 (IGFBP-5) protease that is elevated in preeclampsia, and up-regulated by hypoxia in placental explants. The relationships between PAPP-A2, altitude, and indices of uteroplacental ischemia are unknown. We aimed to evaluate the association of altitude, preeclampsia, and uterine artery flow or vascular resistance with PAPP-A2 levels. PAPP-A2, uterine artery diameter, volumetric blood flow, and pulsatility indices were measured longitudinally in normotensive Andean women residing at low or high altitudes in Bolivia and in a separate Andean high-altitude cohort with or without preeclampsia. PAPP-A2 levels increased with advancing gestation, with the rise tending to be greater at high compared to low altitude, and higher in early-onset preeclamptic compared to normotensive women at high altitude. Uterine artery blood flow was markedly lower and pulsatility index higher in early-onset preeclamptic normotensive women compared to normotensive women. PAPP-A2 was unrelated to uterine artery pulsatility index in normotensive women but positively correlated in the early-onset preeclampsia cases. We concluded that PAPP-A2 is elevated at high altitude and especially in cases of early-onset preeclampsia with Doppler indices of uteroplacental ischemia.
- Published
- 2020
3. The effects of leptin on human cytotrophoblast invasion are gestational age and dose-dependent.
- Author
-
Rumer, Kristen K., Sehgal, Shilpi, Kramer, Anita, Bogart, Kevin P., and Winn, Virginia D.
- Subjects
TROPHOBLAST ,LEPTIN receptors ,GESTATIONAL age ,LEPTIN ,DECIDUA ,CELL communication ,PREECLAMPSIA - Abstract
Introduction: Leptin and its receptors are expressed by the human placenta throughout gestation, yet the role of leptin in early human placental development is not well characterized. Leptin is overexpressed in the placentas from preeclamptic (PE) pregnancies. PE can result from the impaired invasion of fetal placental cells, cytotrophoblasts (CTBs), into the maternal decidua. We hypothesized that elevated leptin levels would impair human CTB invasion. Methods: The effects of leptin on the invasion of human CTBs were evaluated in three cell models, HTR-8/SVneo cells, primary CTBs, and placental villous explants using invasion assays. Further, leptin receptor expression was characterized in all three cell models using RT-PCR. Further phosphokinase assays were performed in HTR-8/SVneo cells to determine signaling pathways involved in CTB invasion in response to differential leptin doses. Results: We found that, prior to 8 weeks gestation, leptin promoted CTB invasion in the explant model. After 11 weeks gestation in explants, primary CTBs and in HTR-8/SVneo cells, leptin promoted invasion at moderate but not at high concentrations. Further, leptin receptor characterization revealed that leptin receptor expression did not vary over gestation, however, STAT, PI3K and MAPK pathways showed different signaling in response to varied leptin doses. Discussion: These data suggest that the excess placental leptin observed in PE may cause impaired CTB invasion as a second-trimester defect. Leptin's differential effect on trophoblast invasion may explain the role of hyperleptinemia in preeclampsia pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Umbilical Cord Blood Circulating Progenitor Cells and Endothelial Colony-Forming Cells Are Decreased in Preeclampsia
- Author
-
Gumina, Diane L., Black, Claudine P., Balasubramaniam, Vivek, Winn, Virginia D., and Baker, Christopher D.
- Published
- 2017
- Full Text
- View/download PDF
5. Proteomic signatures predict preeclampsia in individual cohorts but not across cohorts – implications for clinical biomarker studies.
- Author
-
Ghaemi, Mohammad S., Tarca, Adi L., Romero, Roberto, Stanley, Natalie, Fallahzadeh, Ramin, Tanada, Athena, Culos, Anthony, Ando, Kazuo, Han, Xiaoyuan, Blumenfeld, Yair J., Druzin, Maurice L., El-Sayed, Yasser Y., Gibbs, Ronald S., Winn, Virginia D., Contrepois, Kevin, Ling, Xuefeng B., Wong, Ronald J., Shaw, Gary M., Stevenson, David K., and Gaudilliere, Brice
- Subjects
PROTEOMICS ,PREECLAMPSIA ,PREGNANCY outcomes ,PRENATAL care ,BLOOD proteins - Abstract
Background: Early identification of pregnant women at risk for preeclampsia (PE) is important, as it will enable targeted interventions ahead of clinical manifestations. The quantitative analyses of plasma proteins feature prominently among molecular approaches used for risk prediction. However, derivation of protein signatures of sufficient predictive power has been challenging. The recent availability of platforms simultaneously assessing over 1000 plasma proteins offers broad examinations of the plasma proteome, which may enable the extraction of proteomic signatures with improved prognostic performance in prenatal care. Objective: The primary aim of this study was to examine the generalizability of proteomic signatures predictive of PE in two cohorts of pregnant women whose plasma proteome was interrogated with the same highly multiplexed platform. Establishing generalizability, or lack thereof, is critical to devise strategies facilitating the development of clinically useful predictive tests. A second aim was to examine the generalizability of protein signatures predictive of gestational age (GA) in uncomplicated pregnancies in the same cohorts to contrast physiological and pathological pregnancy outcomes. Study design: Serial blood samples were collected during the first, second, and third trimesters in 18 women who developed PE and 18 women with uncomplicated pregnancies (Stanford cohort). The second cohort (Detroit), used for comparative analysis, consisted of 76 women with PE and 90 women with uncomplicated pregnancies. Multivariate analyses were applied to infer predictive and cohort-specific proteomic models, which were then tested in the alternate cohort. Gene ontology (GO) analysis was performed to identify biological processes that were over-represented among top-ranked proteins associated with PE. Results: The model derived in the Stanford cohort was highly significant (p = 3.9E–15) and predictive (AUC = 0.96), but failed validation in the Detroit cohort (p = 9.7E–01, AUC = 0.50). Similarly, the model derived in the Detroit cohort was highly significant (p = 1.0E–21, AUC = 0.73), but failed validation in the Stanford cohort (p = 7.3E–02, AUC = 0.60). By contrast, proteomic models predicting GA were readily validated across the Stanford (p = 1.1E–454, R = 0.92) and Detroit cohorts (p = 1.1.E–92, R = 0.92) indicating that the proteomic assay performed well enough to infer a generalizable model across studied cohorts, which makes it less likely that technical aspects of the assay, including batch effects, accounted for observed differences. Conclusions: Results point to a broader issue relevant for proteomic and other omic discovery studies in patient cohorts suffering from a clinical syndrome, such as PE, driven by heterogeneous pathophysiologies. While novel technologies including highly multiplex proteomic arrays and adapted computational algorithms allow for novel discoveries for a particular study cohort, they may not readily generalize across cohorts. A likely reason is that the prevalence of pathophysiologic processes leading up to the “same” clinical syndrome can be distributed differently in different and smaller-sized cohorts. Signatures derived in individual cohorts may simply capture different facets of the spectrum of pathophysiologic processes driving a syndrome. Our findings have important implications for the design of omic studies of a syndrome like PE. They highlight the need for performing such studies in diverse and well-phenotyped patient populations that are large enough to characterize subsets of patients with shared pathophysiologies to then derive subset-specific signatures of sufficient predictive power. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Siglec-6 Signaling Uses Src Kinase Tyrosine Phosphorylation and SHP-2 Recruitment.
- Author
-
Stefanski, Adrianne L., Renecle, Michael D., Kramer, Anita, Sehgal, Shilpi, Narasimhan, Purnima, Rumer, Kristen K., and Winn, Virginia D
- Subjects
PHOSPHOPROTEIN phosphatases ,PHOSPHORYLATION ,SITE-specific mutagenesis ,SIALIC acids ,TROPHOBLAST ,PROTEIN-tyrosine phosphatase ,KILLER cell receptors - Abstract
Preeclampsia is a pregnancy-specific disorder involving placental abnormalities. Elevated placental Sialic acid immunoglobulin-like lectin (Siglec)-6 expression has been correlated with preeclampsia. Siglec-6 is a transmembrane receptor, expressed predominantly by the trophoblast cells in the human placenta. It interacts with sialyl glycans such as sialyl-TN glycans as well as binds leptin. Siglec-6 overexpression has been shown to influence proliferation, apoptosis, and invasion in the trophoblast (BeWo) cell model. However, there is no direct evidence that Siglec-6 plays a role in preeclampsia pathogenesis and its signaling potential is still largely unexplored. Siglec-6 contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an ITIM-like motif in its cytoplasmic tail suggesting a signaling function. Site-directed mutagenesis and transfection were employed to create a series of Siglec-6 expressing HTR-8/SVneo trophoblastic cell lines with mutations in specific functional residues to explore the signaling potential of Siglec-6. Co-immunoprecipitation and inhibitory assays were utilized to investigate the association of Src-kinases and SH-2 domain-containing phosphatases with Siglec-6. In this study, we show that Siglec-6 is phosphorylated at ITIM and ITIM-like domains by Src family kinases. Phosphorylation of both ITIM and ITIM-like motifs is essential for the recruitment of phosphatases like Src homology region 2 containing protein tyrosine phosphatase 2 (SHP-2), which has downstream signaling capabilities. These findings suggest Siglec-6 as a signaling molecule in human trophoblasts. Further investigation is warranted to determine which signaling pathways are activated downstream to SHP-2 recruitment and how overexpression of Siglec-6 in preeclamptic placentas impacts pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Siglec-6 Expression Is Increased in Placentas From Pregnancies Complicated by Preterm Preeclampsia
- Author
-
Rumer, Kristen K., Uyenishi, Jill, Hoffman, M. Camille, Fisher, Barbra M., and Winn, Virginia D.
- Published
- 2013
- Full Text
- View/download PDF
8. Inflammatory cytokines, placental pathology, and neurological outcomes in infants born to preterm preeclamptic mothers.
- Author
-
Sotiros, Alexandra, Thornhill, Dianne, Post, Miriam D., Winn, Virginia D., and Armstrong, Jennifer
- Subjects
PREECLAMPSIA ,PLACENTA ,PREMATURE infants ,PREMATURE labor ,PATHOLOGY ,CYTOKINES - Abstract
Preeclampsia is both a vascular and inflammatory disorder. Since the placenta is a conduit for fetal development, preeclampsia should be a presumed cause of adverse infant outcomes. Yet, the relationship of placental pathology, inflammation and neurological outcomes after preeclampsia are understudied. We prospectively examined a cohort of maternal-infant dyads with preeclampsia for maternal inflammatory cytokines at time of preeclampsia diagnosis and delivery, and fetal cord blood cytokines (IL-1β, IL-6, IL-8, and TNF-α). Placentas were analyzed for inflammatory and vascular pathologies. Neurodevelopmental assessment of infants utilizing the Pediatric Stroke Outcome Measure (PSOM) was conducted at 6-month corrected gestational age. Eighty-one maternal-newborn dyads were examined. Worse neurological outcomes were not associated with elevated maternal / fetal cytokines. Early preterm birth (gestational age ≤ 32 weeks) was associated with worse neurological outcomes at 6-months regardless of maternal/ fetal cytokine levels, placental pathology, or cranial ultrasound findings (OR 1.70, [1.16–2.48], p = 0.006). When correcting for gestational age, elevated IL-6 approached significance as a predictor for worse developmental outcome (OR 1.025 [0.985–1.066], p = 0.221). Pathological evidence of maternal malperfusion and worse outcomes were noted in early preterm, although our sample size was small. Our study did not demonstrate an obvious association of inflammation and placental pathology in preeclampsia and adverse neurodevelopmental outcome at 6-month corrected age but does suggest maternal malperfusion at earlier gestational age may be a risk factor for worse outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Changes in pregnancy-related serum biomarkers early in gestation are associated with later development of preeclampsia.
- Author
-
Hao, Shiying, You, Jin, Chen, Lin, Zhao, Hui, Huang, Yujuan, Zheng, Le, Tian, Lu, Maric, Ivana, Liu, Xin, Li, Tian, Bianco, Ylayaly K., Winn, Virginia D., Aghaeepour, Nima, Gaudilliere, Brice, Angst, Martin S., Zhou, Xin, Li, Yu-Ming, Mo, Lihong, Wong, Ronald J., and Shaw, Gary M.
- Subjects
PREECLAMPSIA ,PREGNANCY proteins ,PLACENTAL growth factor ,BLOOD proteins ,PREGNANCY ,PROTEIN-tyrosine kinases - Abstract
Background: Placental protein expression plays a crucial role during pregnancy. We hypothesized that: (1) circulating levels of pregnancy-associated, placenta-related proteins throughout gestation reflect the temporal progression of the uncomplicated, full-term pregnancy, and can effectively estimate gestational ages (GAs); and (2) preeclampsia (PE) is associated with disruptions in these protein levels early in gestation; and can identify impending PE. We also compared gestational profiles of proteins in the human and mouse, using pregnant heme oxygenase-1 (HO-1) heterozygote (Het) mice, a mouse model reflecting PE-like symptoms. Methods: Serum levels of placenta-related proteins–leptin (LEP), chorionic somatomammotropin hormone like 1 (CSHL1), elabela (ELA), activin A, soluble fms-like tyrosine kinase 1 (sFlt-1), and placental growth factor (PlGF)–were quantified by ELISA in blood serially collected throughout human pregnancies (20 normal subjects with 66 samples, and 20 subjects who developed PE with 61 samples). Multivariate analysis was performed to estimate the GA in normal pregnancy. Mean-squared errors of GA estimations were used to identify impending PE. The human protein profiles were then compared with those in the pregnant HO-1 Het mice. Results: An elastic net-based gestational dating model was developed (R
2 = 0.76) and validated (R2 = 0.61) using serum levels of the 6 proteins measured at various GAs from women with normal uncomplicated pregnancies. In women who developed PE, the model was not (R2 = -0.17) associated with GA. Deviations from the model estimations were observed in women who developed PE (P = 0.01). The model developed with 5 proteins (ELA excluded) performed similarly from sera from normal human (R2 = 0.68) and WT mouse (R2 = 0.85) pregnancies. Disruptions of this model were observed in both human PE-associated (R2 = 0.27) and mouse HO-1 Het (R2 = 0.30) pregnancies. LEP outperformed sFlt-1 and PlGF in differentiating impending PE at early human and late mouse GAs. Conclusions: Serum placenta-related protein profiles are temporally regulated throughout normal pregnancies and significantly disrupted in women who develop PE. LEP changes earlier than the well-established biomarkers (sFlt-1 and PlGF). There may be evidence of a causative action of HO-1 deficiency in LEP upregulation in a PE-like murine model. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
10. Maternal Vascular Health in Pregnancy and Postpartum After Assisted Reproduction.
- Author
-
von Versen-Höynck, Frauke, Häckl, Sebastian, Selamet Tierney, Elif Seda, Conrad, Kirk P., Baker, Valerie L., and Winn, Virginia D.
- Abstract
Although most pregnancies after assisted reproduction are associated with a favorable outcome for the mother and infant, reports of abnormal vascular adaptation in early pregnancy and emerging maternal and perinatal pathology warrant further investigations. Herein we extended our previous work and further examined whether perturbations of blood pressure and endothelial function during the first trimester in conceptions with nonphysiological corpus luteum (CL) numbers would persist through the third trimester of pregnancy and into the postpartum period. We investigated both maternal and perinatal outcomes. Participants were grouped according to CL number and method of conception: 0 CL (programmed autologous frozen-thawed embryo transfer, N=10-18); 1 CL (spontaneous conception [N=16] and natural cycle frozen-thawed embryo transfer [N=12]); or >3 CL associated with autologous fresh embryo transfer [N=8-12]. Augmentation index was higher during the third trimester in the absence of a CL compared to 1 CL (P=0.03) and in frozen-thawed embryo transfer in a programmed compared to a natural cycle (P=0.02). Moreover, baseline pulse-wave amplitude was higher in >3 CL conceptions at all time points (all P<0.05). The incidence of preeclampsia and preeclampsia with severe features was significantly higher in the absence of a CL compared to the presence of one or >3 CL (P=0.045 and P=0.03). Infants from conceptions with >3 CL had lower birth weights (P=0.02) and a higher rate of low birth weight offspring (P=0.008). Deficient vascular adaptation during early gestation in conceptions with nonphysiological CL numbers might predispose women to adverse pregnancy outcomes, for example, preeclampsia. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Differential Dynamics of the Maternal Immune System in Healthy Pregnancy and Preeclampsia.
- Author
-
Han, Xiaoyuan, Ghaemi, Mohammad S., Ando, Kazuo, Peterson, Laura S., Ganio, Edward A., Tsai, Amy S., Gaudilliere, Dyani K., Stelzer, Ina A., Einhaus, Jakob, Bertrand, Basile, Stanley, Natalie, Culos, Anthony, Tanada, Athena, Hedou, Julien, Tsai, Eileen S., Fallahzadeh, Ramin, Wong, Ronald J., Judy, Amy E., Winn, Virginia D., and Druzin, Maurice L.
- Subjects
PREECLAMPSIA ,PREGNANCY complications ,IMMUNE system ,PREGNANCY - Abstract
Preeclampsia is one of the most severe pregnancy complications and a leading cause of maternal death. However, early diagnosis of preeclampsia remains a clinical challenge. Alterations in the normal immune adaptations necessary for the maintenance of a healthy pregnancy are central features of preeclampsia. However, prior analyses primarily focused on the static assessment of select immune cell subsets have provided limited information for the prediction of preeclampsia. Here, we used a high-dimensional mass cytometry immunoassay to characterize the dynamic changes of over 370 immune cell features (including cell distribution and functional responses) in maternal blood during healthy and preeclamptic pregnancies. We found a set of eight cell-specific immune features that accurately identified patients well before the clinical diagnosis of preeclampsia (median area under the curve (AUC) 0.91, interquartile range [0.82–0.92]). Several features recapitulated previously known immune dysfunctions in preeclampsia, such as elevated pro-inflammatory innate immune responses early in pregnancy and impaired regulatory T (Treg) cell signaling. The analysis revealed additional novel immune responses that were strongly associated with, and preceded the onset of preeclampsia, notably abnormal STAT5ab signaling dynamics in CD4
+ T cell subsets (AUC 0.92, p = 8.0E-5). These results provide a global readout of the dynamics of the maternal immune system early in pregnancy and lay the groundwork for identifying clinically-relevant immune dysfunctions for the prediction and prevention of preeclampsia. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
12. Placental Expression of Stanniocalcin 2 (STC2) in Healthy and Preeclamptic Pregnancies.
- Author
-
Kjaer, Anna Sophie L., Sehgal, Shilpi, Wu, Yanming, Iyer, Purnima, and Winn, Virginia D.
- Subjects
PREECLAMPSIA ,PLACENTA ,PREGNANCY - Published
- 2023
- Full Text
- View/download PDF
13. Occurrence of Selected Structural Birth Defects Among Women With Preeclampsia and Other Hypertensive Disorders.
- Author
-
Weber, Kari A., Mayo, Jonathan A., Carmichael, Suzan L., Stevenson, David K., Winn, Virginia D., and Shaw, Gary M.
- Subjects
SPINA bifida ,FETAL abnormalities -- Risk factors ,CLEFT lip -- Risk factors ,BIRTH certificates ,DIABETES ,FETAL abnormalities ,HOSPITAL care ,HYPERTENSION in pregnancy ,PREECLAMPSIA ,RELATIVE medical risk ,DISEASE prevalence ,SEVERITY of illness index ,DISEASE risk factors - Abstract
To explore a potential association between preeclampsia and selected birth defects, we examined the prevalence of certain birth defects among women with hypertensive disorders including preeclampsia. We analyzed data from 2,499,536 singleton live births in California from 2007 to 2011, includingmaternal and infant demographics from birth certificates as well as clinical details from delivery hospitalization records. We examined defect groups that were recognizable at birth (e.g., spina bifida and cleft lip). Hypertensive disorders included preexisting hypertension, gestational hypertension, mild preeclampsia, severe preeclampsia/eclampsia, and preeclampsia superimposed on preexisting hypertension. Relative risk values with 95% confidence intervals for each birth defect were calculated by hypertensive group, as well as independent and joint associations of hypertensive and diabetic disorders. Risks of each type of birth defect were higher among offspring of women with hypertensive disorders compared with those without. The risks of birth defects among offspring of women with only a hypertensive disorder were significantly higher than that among women with neither hypertensive nor diabetic disorders (relative risks ranged from 1.37 to 2.77). Risks of birth defects were highest among those born to women with both hypertensive and diabetic disorders compared with those with neither (relative risks ranged from 1.80 to 6.22). These findings support the existence of an association between preeclampsia and certain birth defects and suggest that diabetesmay be a contributing factor. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. A novel in vitro stem cell model to study maternal endothelial function in preeclampsia.
- Author
-
Wu, Yanming, Sun, Tianyanxin, Medina, Pedro, Iyer, Purnima, Stevenson, David K., Wu, Joseph, Sayed, Nazish, and Winn, Virginia D.
- Subjects
STEM cells ,PREECLAMPSIA - Published
- 2023
- Full Text
- View/download PDF
15. Differential expression of human placental PAPP-A2 over gestation and in preeclampsia.
- Author
-
Kramer, Anita W., Lamale-Smith, Leah M., and Winn, Virginia D.
- Subjects
BLASTOCYST ,CHORIONIC villi ,GESTATIONAL age ,PLACENTA ,PREECLAMPSIA ,FIRST trimester of pregnancy ,SECOND trimester of pregnancy ,THIRD trimester of pregnancy ,PREGNANCY proteins ,RESEARCH funding ,CASE-control method - Abstract
Introduction: Pregnancy Associated Plasma Protein A2 (PAPP-A2) is a pregnancy related insulin-like growth factor binding protein-5 (IGFBP-5) protease, known to be elevated in preeclampsia. As the insulin-like growth factors are important in human implantation and placentation, we sought to determine the expression pattern of PAPP-A2 over human gestation in normal and preeclamptic pregnancies to evaluate its role in placental development and the pathogenesis of preeclampsia.Methods: Placental basal plate and chorionic villi samples, maternal and fetal cord blood sera were obtained from preeclamptic and control pregnancies. Formalin-fixed tissue sections from across gestation were stained for cytokeratin-7, HLA-G, and PAPP-A2. PAPP-A2 immunoblot analysis was also performed on protein lysates and sera.Results: PAPP-A2 expression is predominately expressed by differentiated trophoblasts and fetal endothelium. Chorionic villi show strong expression in the first trimester, followed by a progressive decrease in the second trimester, which returns in the third trimester. PAPP-A2 expression is not impacted by labor. PAPP-A2 is increased in the basal plate, chorionic villi and maternal sera in preeclampsia compared to controls, but is not detectable in cord blood.Discussion: PAPP-A2 is differentially expressed in different trophoblast populations and shows strong down regulation in the mid second trimester in chorionic villous samples. Both maternal sera and placental tissue from pregnancies complicated by preeclampsia show increased levels of PAPP-A2. PAPP-A2 levels are not altered by labor. Additionally, PAPP-A2 cannot be detected in cord blood demonstrating that the alterations in maternal and placental PAPP-A2 are not recapitulated in the fetal circulation. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
16. Baseline placental growth factor levels for the prediction of benefit from early aspirin prophylaxis for preeclampsia prevention.
- Author
-
Moore, Gaea S., Allshouse, Amanda A., Winn, Virginia D., Galan, Henry L., and Heyborne, Kent D.
- Subjects
PREECLAMPSIA diagnosis ,PREECLAMPSIA prevention ,ASPIRIN ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,NONSTEROIDAL anti-inflammatory agents ,PREECLAMPSIA ,SECOND trimester of pregnancy ,PREGNANCY proteins ,RESEARCH ,RESEARCH funding ,STATISTICAL sampling ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,PREDICTIVE tests ,BLIND experiment ,RETROSPECTIVE studies - Abstract
Objective: Placental growth factor (PlGF) levels early in pregnancy are lower in women who ultimately develop preeclampsia. Early initiation of low-dose aspirin reduces preeclampsia risk in some high risk women. We hypothesized that low PlGF levels may identify women at increased risk for preeclampsia who would benefit from aspirin.Study Design: Secondary analysis of the MFMU High-Risk Aspirin study including singleton pregnancies randomized to aspirin 60mg/d (n=102) or placebo (n=72), with PlGF collected at 13w 0d-16w 6d. Within the placebo group, we estimated the probability of preeclampsia by PlGF level using logistic regression analysis, then determined a potential PlGF threshold for preeclampsia prediction using ROC analysis. We performed logistic regression modeling for potential confounders.Results: ROC analysis indicated 87.71pg/ml as the threshold between high and low PlGF for preeclampsia-prediction. Within the placebo group high PlGF weakly predicted preeclampsia (AUC 0.653, sensitivity/specificity 63%/66%). We noted a 2.6-fold reduction in preeclampsia with aspirin in the high-PlGF group (12.15% aspirin vs 32.14% placebo, p=0.057), but no significant differences in preeclampsia in the low PlGF group (21.74% vs 15.91%, p=0.445).Conclusions: Unlike other studies, we found that high rather than low PlGF levels were associated with an increased preeclampsia risk. Low PlGF neither identified women at increased risk of preeclampsia nor women who benefitted from aspirin. Further research is needed to determine whether aspirin is beneficial in women with high PlGF, and whether the paradigm linking low PlGF and preeclampsia needs to be reevaluated.Condensation: High-risk women with low baseline PlGF, a risk factor for preeclampsia, did not benefit from early initiation of low-dose aspirin. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
17. Maternal and Fetal Alternative Complement Pathway Activation in Early Severe Preeclampsia.
- Author
-
Hoffman, M. Camille, Rumer, Kristen K., Kramer, Anita, Lynch, Anne M., and Winn, Virginia D.
- Subjects
VERTICAL transmission (Communicable diseases) ,PREECLAMPSIA ,PLACENTA ,ENZYME-linked immunosorbent assay ,CROSS-sectional method ,COMPARATIVE studies - Abstract
Problem We sought to determine whether alternative complement activation fragment Bb (Bb) levels are elevated in the maternal, fetal, and placental blood in cases of severe preeclampsia ( PE) compared with normotensive controls. Method of study This was a cross-sectional study of women admitted at ≥24 weeks gestation with or without severe PE. Maternal plasma was collected at the time of enrollment. Umbilical venous cord and intervillous space blood were collected at delivery. Plasma Bb levels were assessed using ELISA. Bb levels were compared between cases and controls. Results Median Bb levels were higher in the maternal plasma of severe PE subjects ( n = 24) than in controls ( n = 20), 1.45 ± 1.03 versus 0.65 ± 0.23 μg/mL, P < 0.001. In umbilical venous plasma, Bb levels were higher in severe PE subjects ( n = 15) compared with controls ( n = 15), 2.48 ± 1.40 versus 1.01 ± 0.57 μg/mL, P = 0.01. Conclusion Activation fragment Bb is increased in the maternal and umbilical venous blood of cases of severe PE when compared with normotensive controls. These data provide support for alternative complement pathway involvement in the pathogenesis of severe PE and demonstrate that alternative complement activation occurs not only in the maternal but also in the fetal compartment. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
18. Pre-eclampsia is associated with elevated CXCL12 levels in placental syncytiotrophoblasts and maternal blood
- Author
-
Schanz, Andrea, Winn, Virginia D., Fisher, Susan J., Blumenstein, Marion, Heiss, Christian, Hess, Alexandra P., Kruessel, Jan S., Mcmaster, Michael, and North, Robyn A.
- Subjects
- *
PREECLAMPSIA , *PLACENTA , *CHEMOKINES , *EMBRYOLOGY , *SERUM , *BLOOD plasma , *PREGNANCY , *VASCULAR endothelial growth factors - Abstract
Abstract: Objectives: Placental derived vasculogenic/angiogenic substances in maternal blood are dysregulated in pre-eclampsia. We hypothesized that CXCL12, a chemokine with vasculogenic actions, is amongst such molecules. Study design: CXCL12, CXCL16, CXCR4, and CXCR6 immunolocalization in placental tissue was analyzed in pre-eclampsia (n =8) in comparison to controls (n =8). CXCL12, measured by ELISA in blood, in women diagnosed with pre-eclampsia (n =14) and prior to the development of pre-eclampsia (at 20 weeks’ gestation, n =20) was compared with CXCL12 concentrations in gestation-matched, healthy control subjects (n =34). Results: In placental tissue, syncytiotrophoblast staining for CXCL12 was increased in pre-eclampsia. Maternal serum CXCL12 was increased in pre-eclampsia [2000 (SD 402) vs 1484 (SD 261)pg/ml, P =0.01] but not in plasma obtained at 20 weeks of gestation prior to the onset of pre-eclampsia [1183 (SD 336) vs 1036 (SD 144)pg/ml, P =0.09]. Conclusion: Our data suggest that the syncytiotrophoblast contributes to a pre-eclampsia-associated increase in CXCL12 levels in maternal blood. These findings support the hypothesis that an imbalance of angiogenic factors contributes to the pathogenesis of pre-eclampsia. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
19. The impact of preeclampsia on gene expression at the maternal–fetal interface.
- Author
-
Winn, Virginia D., Gormley, Matthew, and Fisher, Susan J.
- Subjects
PREECLAMPSIA ,PREGNANCY ,HYPERTENSION ,PROTEINURIA ,GENE expression - Abstract
Abstract: Preeclampsia (PE) impacts 8 million mother–infant pairs worldwide each year. This human pregnancy-specific disease characterized by hypertension and proteinuria accounts for significant maternal and neonatal morbidity and mortality. The current theory of the pathogenesis of PE as reviewed by Dr. Christopher Redman and Dr. Ian Sargent is thought to occur as a 2-stage process with poor placentation in the first half of pregnancy resulting in the maternal response in the second half of pregnancy. Our studies have focused on understanding the placental contribution to this serious disease by examining the gene expression profile of the deciduas basalis or basal plate, the region of the placenta involved in the “poor placentation”. In this review we present summaries of our microarray datasets both of normal placentation and those of gene expression changes resulting in the context of PE. Additionally, we have taken this opportunity to combine the datasets to provide a more comprehensive view of this region of the placenta. As defects in the basal plate are, in part, at the root of the disease process, we believe that understanding the pathobiology that occurs in this region will increase our ability to alter the development and/or course of PE. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.